As part of a Ludwig Cancer Research study, a team has devised a “STOP-CAR-T” system that reversibly inactivates CAR-T cells via small molecules. The approach is intended to dampen the effects of CAR-T cell therapy when adverse reactions occur in patients. Although CAR-T therapies have been praised for their success, they can sometimes elicit cytokine release syndrome. To build STOP-CAR-T, the researchers attached the CD3-zeta activation domain to one molecule and the antigen-detecting portion to another. They also added to each chain the interacting domains of two unrelated proteins that spontaneously pair up inside the cell. This allows them to function as a single unit; however, the binding can be disrupted by systemically administered small molecules. So far, the system has only been tested in cell cultures and in mice.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
References
- G Giordano-Attianese et al., Nature Biotechnology (2020).
